Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Reuters Investment Profile
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: New Constructs, LLC
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Cerus Corp Prices Public Offering Of Common Stock


Thursday, 14 Mar 2013 09:15am EDT 

Cerus Corp announced that the pricing of an underwritten public offering of 8,333,333 shares of its common stock, offered at a price to the public of $4.20 per share. The gross proceeds to Cerus from this offering are expected to be approximately $35.0 million, before deducting the underwriting discount and other estimated offering expenses payable by Cerus. The offering is expected to close on or about March 19, 2013, subject to customary closing conditions. In addition, Cerus has granted the underwriters a 30-day option to purchase at the public offering price up to an aggregate of 1,250,000 additional shares of its common stock to cover overallotments, if any. Cerus anticipates using the net proceeds from the offering for clinical development and other research and development activities related to the INTERCEPT Blood System, preparatory activities for the potential commercialization of the INTERCEPT Blood System in the United States and elsewhere, and for other general corporate purposes, including regulatory activity, selling, general and administrative expenses and working capital. Cowen and Company, LLC is acting as sole book-running manager for the offering. Robert W. Baird & Co. Incorporated, Wedbush PacGrow Life Sciences and Lazard Capital Markets LLC are acting as co-managers for the offering. Blueprint Life Science Group, LLC and MLV & Co. LLC are acting as Cerus` financial advisors in connection with the offering. 

Company Quote

4.26
-0.03 -0.70%
21 Nov 2014